Update 24 August 2022
The Australian National COVID-19 Clinical Evidence Taskforce has issued a strong recommendation against the use of ivermectin outside of randomised clinical trials.
The Taskforce found the available research evidence suggests that ivermectin does not decrease mortality, the need for supplemental oxygen or the need for hospitalisation for people with COVID-19. It also may increase the chance of side effects.
Ivermectin is currently being investigated in the UK as part of the Platform Randomised Trial of Treatments in the Community for Epidemic and Pandemic Illnesses (PRINCIPLE) study, led by the University of Oxford. PRINCIPLE is investigating treatments that can speed up recovery, reduce the severity of symptoms and prevent the need for hospital admission in people at risk of serious illness from COVID-19. The study has so far recruited more than 11,000 volunteers.
On 10 September 2021 the Therapeutic Goods Administration (TGA) placed new restrictions on the prescribing of oral ivermectin. With the introduction of these restrictions, GPs can only prescribe ivermectin for TGA-approved conditions, scabies and certain parasitic infections. Specialists including infectious disease physicians, dermatologists, gastroenterologists and hepatologists (liver disease specialists) will be permitted to prescribe ivermectin for other unapproved indications if they believe it is appropriate for a particular patient.